Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy—The BIOCRT Study

摘要

BackgroundCardiac resynchronization therapy (CRT) improves mitral regurgitation (MR) in a subset of patients. We hypothesized that biomarkers (amino-terminal pro-B type natriuretic peptide [NT-proBNP], high-sensitivity troponin [hsTnI], galectin-3 [gal-3] and soluble ST-2 [sST2]) may predict MR response post-CRT.